Denali Therapeutics Q4 2021 Earnings Report
Key Takeaways
Denali Therapeutics reported a net loss of $75.3 million for the fourth quarter of 2021, compared to a net income of $244.9 million for the same period in 2020. Collaboration revenue decreased to $12.5 million from $316.8 million year-over-year, primarily due to a decrease in revenue recognized under the Biogen collaboration agreement. The company anticipates an increase of approximately 25-30% in cash operating expenses compared to 2021.
Details on study designs for two late-stage clinical trials of BIIB122/DNL151 in Parkinson’s disease (PD) were announced.
Interim data from the Phase 1/2 clinical trial of DNL310 at the WORLDSymposium™ on lysosomal diseases was presented.
Recruiting continues in a Phase 1b clinical trial of DNL343 expected to enroll approximately 30 participants with amyotrophic lateral sclerosis (ALS).
Sanofi plans to begin dosing with SAR443820 in the HIMALAYA Phase 2 trial in participants with ALS in Q1 2022.
Denali Therapeutics
Denali Therapeutics
Denali Therapeutics Revenue by Segment
Forward Guidance
For 2022, Denali anticipates an increase of approximately 25-30% in cash operating expenses compared to 2021, offset by approximately $100 million from incoming cash and milestones from Denali's current partnerships.